Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

Henry Childs

dblp:376/9136 · DBLP profile ↗
← Back
1ranked-venue papers
0as first author
1since 2021 · last 2024
—ORCID · unresolved

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 1 · 1 since 2021

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 100%
Theoretical computer science
1 paper
Mathematical optimization · 100%

Topics — the 4 heaviest of 5, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology › drug discovery › peptide drug discovery
peptide inhibitor design
0.812024
DexDesign: A New OSPREY-Based Algorithm for Designing de novo D-peptide Inhibitors · RECOMB 2024
Bioinformatics and computational biology
protein design
0.812024
DexDesign: A New OSPREY-Based Algorithm for Designing de novo D-peptide Inhibitors · RECOMB 2024
Mathematical optimization
combinatorial optimization
0.812024
DexDesign: A New OSPREY-Based Algorithm for Designing de novo D-peptide Inhibitors · RECOMB 2024
Mathematical optimization › multi-objective optimization
pareto optimization
0.812024
DexDesign: A New OSPREY-Based Algorithm for Designing de novo D-peptide Inhibitors · RECOMB 2024

Methods — techniques the papers use, named apart from their topics

pareto optimization · 1.5OSPREY · 1.5
YearPublicationVenuePosition
2024 DexDesign: A New OSPREY-Based Algorithm for Designing de novo D-peptide Inhibitors
Nathan Guerin, Henry Childs, Pei Zhou 0001, Bruce Randall Donald
RECOMB2